Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12480539 | 0.82 | GRM2 (0.43) | SMN1; SMN2ALDH1A1LMNAGRM2MMP1 | |
| SCHEMBL12480535 | 0.82 | GRM2 (0.43) | SMN1; SMN2ALDH1A1LMNAGRM2MMP1 | |
| SCHEMBL12480241 | 0.82 | GRM2 (0.43) | SMN1; SMN2ALDH1A1LMNAGRM2MMP1 | |
| SCHEMBL2798499 | 0.75 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1LMNAGAASIGMAR1 | |
| SCHEMBL27810603 | 0.74 | GRM2 (0.42) | ALDH1A1LMNAGRM2MMP1MMP13 | |
| SCHEMBL20061327 | 0.71 | GAA (0.50) | SMN1; SMN2ALDH1A1LMNAGRM2GAA | |
| SCHEMBL20061443 | 0.70 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1LMNAGRM2GAA | |
| SCHEMBL20061523 | 0.69 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1LMNAGRM2MMP1 | |
| SCHEMBL20061521 | 0.69 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1LMNAGRM2GAA | |
| SCHEMBL20061519 | 0.68 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1LMNAGRM2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117157297-A | PRMT5 inhibitors | 上海齐鲁制药研究中心有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | SMN1; SMN2 4250/4885ALDH1A1 3849/4885LMNA 1430/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | SMN1; SMN2 4250/4885ALDH1A1 3849/4885LMNA 1430/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | SMN1; SMN2 4250/4885ALDH1A1 3849/4885LMNA 1430/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | SMN1; SMN2 4501/4885ALDH1A1 3868/4885LMNA 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.